SUFLAVE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Suflave, and when can generic versions of Suflave launch?
Suflave is a drug marketed by Braintree Labs and is included in one NDA.
The generic ingredient in SUFLAVE is magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate profile page.
Summary for SUFLAVE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SUFLAVE |
| What excipients (inactive ingredients) are in SUFLAVE? | SUFLAVE excipients list |
| DailyMed Link: | SUFLAVE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SUFLAVE
Generic Entry Date for SUFLAVE*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
FOR SOLUTION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for SUFLAVE
US Patents and Regulatory Information for SUFLAVE
SUFLAVE is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SUFLAVE is ⤷ Try a Trial.
This potential generic entry date is based on NEW PRODUCT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting SUFLAVE
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braintree Labs | SUFLAVE | magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate | FOR SOLUTION;ORAL | 215344-001 | Jun 15, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
